The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for ...

David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

Companies argue they’re filling a need created by these miracle weight-loss drugs. But are they offering something of real ...

One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.

Food companies are rushing to reformulate products for protein lovers. That’s a category that includes both people taking the powerful new class of obesity drugs known as GLP-1s, who are ...

Just five sell-side analysts rate Apple Inc.’s stock at the equivalent of sell, counting Jefferies’ Edison Lee, who turned bearish late Monday. Lee has three reasons for his pessimism, as he t ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...